Healthcare delivery for HIV-positive people with tuberculosis in Europe

A K Bentzon; A Panteleev; V Mitsura; E Borodulina; A Skrahina; E Denisova; S Tetradov; R Podlasin; V Riekstina; Z Kancauskiene; D Paduto; A Mocroft; T Trofimova; R Miller; F Post; A Grezesczuk; J D Lundgren; M Inglot; D Podlekareva; N Bolokadze; O Kirk; TB:HIV Study Group

doi:10.1111/hiv.13016

Healthcare delivery for HIV-positive people with tuberculosis in Europe

A K Bentzon, A Panteleev, V Mitsura, E Borodulina, A Skrahina, E Denisova, S Tetradov, R Podlasin, V Riekstina, Z Kancauskiene, D Paduto, A Mocroft, T Trofimova, R Miller, F Post, A Grezesczuk, J D Lundgren, M Inglot, D Podlekareva, N BolokadzeO Kirk, TB:HIV Study Group

Afdeling for Infektionssygdomme

9 Citationer (Scopus)

Abstract

BACKGROUND: In a 2013 survey, we reported distinct discrepancies in delivery of tuberculosis (TB) and HIV services in eastern Europe (EE) vs. western Europe (WE).

OBJECTIVES: To verify the differences in TB and HIV services in EE vs. WE.

METHODS: Twenty-three sites completed a survey in 2018 (EE, 14; WE, nine; 88% response rate). Results were compared across as well as within the two regions. When possible, results were compared with the 2013 survey.

RESULTS: Delivery of healthcare was significantly less integrated in EE: provision of TB and HIV services at one site (36% in EE vs. 89% in WE; P = 0.034), and continued TB follow-up in one location (42% vs. 100%; P = 0.007). Although access to TB diagnostics, standard TB and HIV drugs was generally good, fewer sites in EE reported unlimited access to rifabutin/multi-drug-resistant TB (MDR-TB) drugs, HIV integrase inhibitors and opioid substitution therapy (OST). Compared with 2013, routine usage of GeneXpert was more common in EE in 2018 (54% vs. 92%; P = 0.073), as was access to moxifloxacin (46% vs. 91%; P = 0.033), linezolid (31% vs. 64%; P = 0.217), and bedaquiline (0% vs. 25%; P = 0.217). Integration of TB and HIV services (46% vs. 39%; P = 1.000) and provision of OST to patients with opioid dependency (54% vs. 46%; P = 0.695) remained unchanged.

CONCLUSION: Delivery of TB and HIV healthcare, including integration of TB and HIV care and access to MDR-TB drugs, still differs between WE and EE, as well as between individual EE sites.

Originalsprog	Engelsk
Tidsskrift	HIV Medicine
Vol/bind	22
Udgave nummer	4
Sider (fra-til)	283-293
Antal sider	11
ISSN	1464-2662
DOI	https://doi.org/10.1111/hiv.13016
Status	Udgivet - apr. 2021

Adgang til dokumentet

10.1111/hiv.13016

Citationsformater

Bentzon, A. K., Panteleev, A., Mitsura, V., Borodulina, E., Skrahina, A., Denisova, E., Tetradov, S., Podlasin, R., Riekstina, V., Kancauskiene, Z., Paduto, D., Mocroft, A., Trofimova, T., Miller, R., Post, F., Grezesczuk, A., Lundgren, J. D., Inglot, M., Podlekareva, D., ... TB:HIV Study Group (2021). Healthcare delivery for HIV-positive people with tuberculosis in Europe. HIV Medicine, 22(4), 283-293. https://doi.org/10.1111/hiv.13016

Bentzon, AK, Panteleev, A, Mitsura, V, Borodulina, E, Skrahina, A, Denisova, E, Tetradov, S, Podlasin, R, Riekstina, V, Kancauskiene, Z, Paduto, D, Mocroft, A, Trofimova, T, Miller, R, Post, F, Grezesczuk, A, Lundgren, JD, Inglot, M, Podlekareva, D, Bolokadze, N, Kirk, O & TB:HIV Study Group 2021, 'Healthcare delivery for HIV-positive people with tuberculosis in Europe', HIV Medicine, bind 22, nr. 4, s. 283-293. https://doi.org/10.1111/hiv.13016

@article{96f9ebea96164588b5df0ea482f06e95,

title = "Healthcare delivery for HIV-positive people with tuberculosis in Europe",

abstract = "BACKGROUND: In a 2013 survey, we reported distinct discrepancies in delivery of tuberculosis (TB) and HIV services in eastern Europe (EE) vs. western Europe (WE).OBJECTIVES: To verify the differences in TB and HIV services in EE vs. WE.METHODS: Twenty-three sites completed a survey in 2018 (EE, 14; WE, nine; 88% response rate). Results were compared across as well as within the two regions. When possible, results were compared with the 2013 survey.RESULTS: Delivery of healthcare was significantly less integrated in EE: provision of TB and HIV services at one site (36% in EE vs. 89% in WE; P = 0.034), and continued TB follow-up in one location (42% vs. 100%; P = 0.007). Although access to TB diagnostics, standard TB and HIV drugs was generally good, fewer sites in EE reported unlimited access to rifabutin/multi-drug-resistant TB (MDR-TB) drugs, HIV integrase inhibitors and opioid substitution therapy (OST). Compared with 2013, routine usage of GeneXpert was more common in EE in 2018 (54% vs. 92%; P = 0.073), as was access to moxifloxacin (46% vs. 91%; P = 0.033), linezolid (31% vs. 64%; P = 0.217), and bedaquiline (0% vs. 25%; P = 0.217). Integration of TB and HIV services (46% vs. 39%; P = 1.000) and provision of OST to patients with opioid dependency (54% vs. 46%; P = 0.695) remained unchanged.CONCLUSION: Delivery of TB and HIV healthcare, including integration of TB and HIV care and access to MDR-TB drugs, still differs between WE and EE, as well as between individual EE sites.",

keywords = "clinical management, coinfection, eastern Europe, HIV, tuberculosis, western Europe",

author = "Bentzon, {A K} and A Panteleev and V Mitsura and E Borodulina and A Skrahina and E Denisova and S Tetradov and R Podlasin and V Riekstina and Z Kancauskiene and D Paduto and A Mocroft and T Trofimova and R Miller and F Post and A Grezesczuk and Lundgren, {J D} and M Inglot and D Podlekareva and N Bolokadze and O Kirk and {TB:HIV Study Group}",

note = "{\textcopyright} 2020 British HIV Association.",

year = "2021",

month = apr,

doi = "10.1111/hiv.13016",

language = "English",

volume = "22",

pages = "283--293",

journal = "HIV Medicine",

issn = "1464-2662",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - Healthcare delivery for HIV-positive people with tuberculosis in Europe

AU - Bentzon, A K

AU - Panteleev, A

AU - Mitsura, V

AU - Borodulina, E

AU - Skrahina, A

AU - Denisova, E

AU - Tetradov, S

AU - Podlasin, R

AU - Riekstina, V

AU - Kancauskiene, Z

AU - Paduto, D

AU - Mocroft, A

AU - Trofimova, T

AU - Miller, R

AU - Post, F

AU - Grezesczuk, A

AU - Lundgren, J D

AU - Inglot, M

AU - Podlekareva, D

AU - Bolokadze, N

AU - Kirk, O

AU - TB:HIV Study Group

PY - 2021/4

Y1 - 2021/4

N2 - BACKGROUND: In a 2013 survey, we reported distinct discrepancies in delivery of tuberculosis (TB) and HIV services in eastern Europe (EE) vs. western Europe (WE).OBJECTIVES: To verify the differences in TB and HIV services in EE vs. WE.METHODS: Twenty-three sites completed a survey in 2018 (EE, 14; WE, nine; 88% response rate). Results were compared across as well as within the two regions. When possible, results were compared with the 2013 survey.RESULTS: Delivery of healthcare was significantly less integrated in EE: provision of TB and HIV services at one site (36% in EE vs. 89% in WE; P = 0.034), and continued TB follow-up in one location (42% vs. 100%; P = 0.007). Although access to TB diagnostics, standard TB and HIV drugs was generally good, fewer sites in EE reported unlimited access to rifabutin/multi-drug-resistant TB (MDR-TB) drugs, HIV integrase inhibitors and opioid substitution therapy (OST). Compared with 2013, routine usage of GeneXpert was more common in EE in 2018 (54% vs. 92%; P = 0.073), as was access to moxifloxacin (46% vs. 91%; P = 0.033), linezolid (31% vs. 64%; P = 0.217), and bedaquiline (0% vs. 25%; P = 0.217). Integration of TB and HIV services (46% vs. 39%; P = 1.000) and provision of OST to patients with opioid dependency (54% vs. 46%; P = 0.695) remained unchanged.CONCLUSION: Delivery of TB and HIV healthcare, including integration of TB and HIV care and access to MDR-TB drugs, still differs between WE and EE, as well as between individual EE sites.

AB - BACKGROUND: In a 2013 survey, we reported distinct discrepancies in delivery of tuberculosis (TB) and HIV services in eastern Europe (EE) vs. western Europe (WE).OBJECTIVES: To verify the differences in TB and HIV services in EE vs. WE.METHODS: Twenty-three sites completed a survey in 2018 (EE, 14; WE, nine; 88% response rate). Results were compared across as well as within the two regions. When possible, results were compared with the 2013 survey.RESULTS: Delivery of healthcare was significantly less integrated in EE: provision of TB and HIV services at one site (36% in EE vs. 89% in WE; P = 0.034), and continued TB follow-up in one location (42% vs. 100%; P = 0.007). Although access to TB diagnostics, standard TB and HIV drugs was generally good, fewer sites in EE reported unlimited access to rifabutin/multi-drug-resistant TB (MDR-TB) drugs, HIV integrase inhibitors and opioid substitution therapy (OST). Compared with 2013, routine usage of GeneXpert was more common in EE in 2018 (54% vs. 92%; P = 0.073), as was access to moxifloxacin (46% vs. 91%; P = 0.033), linezolid (31% vs. 64%; P = 0.217), and bedaquiline (0% vs. 25%; P = 0.217). Integration of TB and HIV services (46% vs. 39%; P = 1.000) and provision of OST to patients with opioid dependency (54% vs. 46%; P = 0.695) remained unchanged.CONCLUSION: Delivery of TB and HIV healthcare, including integration of TB and HIV care and access to MDR-TB drugs, still differs between WE and EE, as well as between individual EE sites.

KW - clinical management

KW - coinfection

KW - eastern Europe

KW - HIV

KW - tuberculosis

KW - western Europe

U2 - 10.1111/hiv.13016

DO - 10.1111/hiv.13016

M3 - Journal article

C2 - 33215809

SN - 1464-2662

VL - 22

SP - 283

EP - 293

JO - HIV Medicine

JF - HIV Medicine

IS - 4

ER -

Healthcare delivery for HIV-positive people with tuberculosis in Europe

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater